1-Deamino-8-D-arginine vasopressin as a therapy for the bleeding diathesis of renal failure.
The treatment of the bleeding diathesis of renal failure remains unsatisfactory. 1-Deamino-8-D-arginine vasopressin (DDAVP) has recently been shown to shorten the prolonged bleeding time of renal failure and may as a result diminish the risk of clinical hemorrhage. We describe 2 cases where DDAVP was used successfully in the management of hemorrhage in the setting of renal insufficiency.
D058186:Acute Kidney Injury / Q000150:complications*; D000368:Aged; D001127:Arginine Vasopressin / Q000627:therapeutic use*; D001760:Bleeding Time; D003894:Deamino Arginine Vasopressin / Q000627:therapeutic use*; D005260:Female; D006474:Hemorrhagic Disorders / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D008297:Male
D001127:Arginine Vasopressin; D003894:Deamino Arginine Vasopressin